JP2005529152A5 - - Google Patents

Download PDF

Info

Publication number
JP2005529152A5
JP2005529152A5 JP2004505078A JP2004505078A JP2005529152A5 JP 2005529152 A5 JP2005529152 A5 JP 2005529152A5 JP 2004505078 A JP2004505078 A JP 2004505078A JP 2004505078 A JP2004505078 A JP 2004505078A JP 2005529152 A5 JP2005529152 A5 JP 2005529152A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
dose
antibody
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004505078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005529152A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/015874 external-priority patent/WO2003097082A2/en
Publication of JP2005529152A publication Critical patent/JP2005529152A/ja
Publication of JP2005529152A5 publication Critical patent/JP2005529152A5/ja
Pending legal-status Critical Current

Links

JP2004505078A 2002-05-17 2003-05-16 抗インターフェロンγ抗体を用いたクローン病又は乾癬の治療 Pending JP2005529152A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15074202A 2002-05-17 2002-05-17
US38331002P 2002-05-22 2002-05-22
PCT/US2003/015874 WO2003097082A2 (en) 2002-05-17 2003-05-16 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies

Publications (2)

Publication Number Publication Date
JP2005529152A JP2005529152A (ja) 2005-09-29
JP2005529152A5 true JP2005529152A5 (OSRAM) 2006-07-06

Family

ID=29552737

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004505078A Pending JP2005529152A (ja) 2002-05-17 2003-05-16 抗インターフェロンγ抗体を用いたクローン病又は乾癬の治療

Country Status (5)

Country Link
EP (1) EP1506002A4 (OSRAM)
JP (1) JP2005529152A (OSRAM)
AU (1) AU2003231802A1 (OSRAM)
CA (1) CA2486147A1 (OSRAM)
WO (1) WO2003097082A2 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE173630T1 (de) 1992-12-29 1998-12-15 Genentech Inc Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
ES2381203T3 (es) * 2005-01-27 2012-05-24 Novimmune Sa Anticuerpos anti-interferón gamma humanos y métodos de uso de los mismos
AU2006342608A1 (en) * 2006-04-25 2007-11-01 Intercell Ag HCV vaccinations
TWI461210B (zh) * 2008-03-18 2014-11-21 Abbvie Inc 治療牛皮癬的方法
KR20140097336A (ko) 2011-11-23 2014-08-06 암젠 인크 인터페론 감마에 대한 항체를 이용한 치료 방법
MA41271A (fr) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
JP2018515493A (ja) 2015-05-07 2018-06-14 ノビミューン エスアー Ｃｘｃｌ９および他のバイオマーカーのレベルが上昇した患者における障害の診断および治療のための方法および組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE173630T1 (de) * 1992-12-29 1998-12-15 Genentech Inc Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
CA2297692A1 (en) * 1997-08-18 1999-02-25 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
WO2000032634A1 (en) 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
US20050019323A1 (en) * 2002-05-22 2005-01-27 Protein Design Labs, Inc. Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies

Similar Documents

Publication Publication Date Title
JP2019196370A5 (OSRAM)
JP2015187125A5 (OSRAM)
JP2020002172A5 (OSRAM)
HRP20170056T2 (hr) Terapija male učestalosti glatiramer acetatom
JP2017031213A5 (OSRAM)
JP2016074740A5 (OSRAM)
EP2433650A3 (en) Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
JP2014114288A5 (OSRAM)
KR101900520B1 (ko) 복합 조성물
JP2005520778A5 (OSRAM)
JP2013533858A5 (OSRAM)
JP2016516016A5 (OSRAM)
JP2017537105A5 (OSRAM)
RU2014101207A (ru) Новые показания к применению при лечении антителами против il-1-бета
JP2018531938A5 (OSRAM)
FI3356386T3 (fi) Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä
JP2015172060A5 (OSRAM)
JP2020515530A5 (OSRAM)
IL292706A (en) Type i interferon inhibition in systemic lupus erythematosus
JP2005506345A5 (OSRAM)
JP2006508039A5 (OSRAM)
JP2019521156A5 (OSRAM)
IL307751B1 (en) Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
JP2005529152A5 (OSRAM)
JP2006514681A5 (OSRAM)